Antidepressant Exposure and Risk of Fracture Among Medicaid-Covered Youth.
This study examines the association between antidepressant use and risk of fracture in depressed youth and assesses whether fracture incidence varies over the course of antidepressant treatment.



A retrospective cohort analysis of Ohio Medicaid claims data was conducted for youth ages 6-17 years with a new episode of ICD-9-diagnosed depression from 2001-2009. The primary outcome variable was time to fracture. Fracture rates were compared between depressed youth treated with antidepressant medication and untreated depressed youth. Time categories of no use, past use, and current use were compared.



Of 50,673 depressed youths, 5,872 (11.6%) experienced a fracture. Of those who had a fracture, 2,228 (37.9%) were exposed to antidepressants, 80% of which were selective serotonin reuptake inhibitors. The adjusted hazard ratio (HR) was 3% higher in those currently prescribed antidepressants (HR = 1.03; 95% CI, 1.00-1.06; P = .03). The risk ratio (RR) for adjusted fracture rates per 10,000 persons was twice as high during the first 30 days of antidepressant use compared to the other time periods (RR = 2.0; 95% CI, 1.2-3.3; P = .007). The number of fractures for those with past antidepressant use did not differ from those with no history of antidepressant use.



Antidepressant use may be associated with a small but significant increase in fracture risk, particularly within the first 30 days of treatment. Findings underscore a need for additional prospective and mechanistic research. Prescribers should consider other risks for fracture in antidepressant-treated youth, particularly disability and the concomitant use of other medications that increase fracture risk.
Nationwide Children's Hospital, 700 Children's Dr, J West 4923, Columbus, OH 43205. Barbara.Gracious@nationwidechildrens.org.|Department of Psychiatry and Behavioral Health, The Ohio State University Wexner Medical Center, Columbus.|Center for Innovation in Pediatric Practice, The Research Institute at Nationwide Children's Hospital, Nationwide Children's Hospital, Columbus, Ohio, USA.
Barbara L
BL
Gracious
Department of Psychiatry and Behavioral Health, The Ohio State University Wexner Medical Center, Columbus.
Cynthia A
CA
Fontanella
Center for Biostatistics, The Ohio State University, Columbus.
Gary S
GS
Phillips
Center for Innovation in Pediatric Practice, The Research Institute at Nationwide Children's Hospital, Nationwide Children's Hospital, Columbus, Ohio, USA.|Department of Pediatrics, The Ohio State University, Columbus.
Jeffrey A
JA
Bridge
Center for Health Equity Research & Promotion, Philadelphia Veterans Affairs Medical Center, Pennsylvania, USA.|School of Social Policy & Practice, University of Pennsylvania, Philadelphia.
Steven C
SC
Marcus
Department of Psychiatry and Behavioral Health, The Ohio State University Wexner Medical Center, Columbus.
John V
JV
Campo
D000293:Adolescent; D000928:Antidepressive Agents / Q000009:adverse effects*; D016022:Case-Control Studies; D002648:Child; D005260:Female; D050723:Fractures, Bone / Q000139:chemically induced / Q000453:epidemiology*; D006801:Humans; D015994:Incidence; D008297:Male; D008484:Medicaid / Q000706:statistics & numerical data; D009820:Ohio / Q000453:epidemiology; D012189:Retrospective Studies; D012307:Risk Factors; D013997:Time Factors; D014481:United States
D000928:Antidepressive Agents